Levofloxacin-based triple therapies are regarded as the typical therapy for Helicobacter pylori (H. pylori) eradication due to reduced sensitivity to clarithromycin. This pilot prospective randomized study proved that levofloxacin-dexlansoprazole based therapy had maximum eradication rate for this bacterial infection when used for 10 days.

To determine the i). Efficacy of triple therapy based on levofloxacin-dexlansoprazole as a usual therapy for H. pylori infection and ii). Assess the effect of H. pylori on lipid panel and hemoglobin (Hb).

This study comprised of 66 patients with H. pylori infection on triple therapy [(Levofloxacin 500 mg/day, Amoxicillin 1 g/12 hours, Dexlansoprazole 60 mg/day, LAD] administrated orally for either 7 or 10 days. The stool antigen test was used to assess eradictation 4 weeks following the therapy.

Eradication rate was 63.6% in patients on LAD therapy for 7 days as compared to 90.9% when used for 10 days. Considerable difference in low-density and high-density lipoprotein, triglyceride, Hb and total cholesterol levels prior to and following the therapy was observed.

The use of LAD treatment for a period of 10 days is the least time that offers maximum efficacy for H. Pylori infection. Additionally, efficacious therapy of H. pylori infection may lessen anemia and dyslipidemia risk. All the members of the patient's family should be examined for H. pylori to decrease the chances of repeated infection.